Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05504356

Volunteers to Investigate Best Results for Ablation and Novel Therapies for Atrial Fibrillation

VIBRANT-AF seeks to:

* Identify clinically relevant predictors of effectiveness and complications of AF ablation procedures in a prospective, US-based, multi-center, real-world longitudinal study * Assess changes in modifiable lifestyle-related exposures influence the effectiveness of AF ablation * Determine incidence and predictors of complications of AF ablation procedures

Participants will connect with the Eureka Research Platform and answer a series of surveys and activities over a one-year period. They will be asked about lifestyle habits, recurrence of AFib, hospitalizations, and general feelings and emotions.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of California, San Francisco

San Francisco, California, 94143, United States

Location status: Recruiting

Location contact

Greg Marcus

CONTACT

[email protected]

About this study

Catheter ablation for Atrial Fibrillation is the most commonly performed cardiac electrophysiology procedure. Although now standard of care in professional society guidelines, recommendations favoring the procedure are predominately based on randomized trials or single-center experiences from high-volume institutions staffed by expert operators. Participants enrolled in those randomized trials are healthier than those undergoing the procedure in the "real world," and the actual experiences of patients throughout the US are not represented by those referred to tertiary-referral centers that most frequently publish their retrospective observations. Although administrative databases provide a glimpse into what happens in the real-world, ICD-9, ICD-10, and CPT codes cannot capture specific procedural approaches or patient perspectives. For this reason, this study aims to leverage the Eureka Research Platform, a digital health infrastructure to enable longitudinal follow-up and ascertainment of patient reported outcomes.

This is a longitudinal, observational cohort study. 15,000 subjects are planned to be enrolled, and will be followed for a period of one year. Subjects will be asked weekly survey questions on weekly habits, complications, medication usage, and hospitalizations. They will have the option to receive AliveCor Kardia devices for remote ECG monitoring, as well as connect their Apple HealthKit data. Surveys will be conducted via the Eureka mobile app.

In conjunction with the Eureka Research Platform, the study will leverage the AF Ablation National Cardiovascular Data Registry (NCDR) run by the American College of Cardiology (ACC). This rapidly growing registry includes comprehensive data regarding patient, procedure, and institution-level characteristics, now includes over 200 institutions around the US, and has already enrolled more than 47,000 patients. However, the registry is limited to data collected during the index procedure visit, without longitudinal follow-up or patient reported outcomes. The study will link the Eureka Research Platform data to NCDR registry data on the index procedure for a subset of participants, allowing for analysis of longitudinal follow-up together with index procedure data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults age 18 and older
  • Must have a smartphone device (iOS and/or Android) and cell phone number to participate on the mobile app, and will be willing to download the Eureka Research Platform mobile application
  • Must have email address to participate on the web portal (accessible on any web-connected device)
  • Undergone a catheter ablation procedure for atrial fibrillation in the week prior to recruitment, or have an ablation planned for within a week from recruitment

Exclusion criteria

  • Unable to consent for themselves
  • Unable to read, speak, comprehend English

Treatment and study plan

Primary outcomes

  1. Time to Atrial Fibrillation Recurrence

    Time frame: 1 year

    Time to atrial fibrillation, after employing a 3-month blanking period. Atrial Fibrillation Recurrence includes patient-reported symptoms of AF or Kardia-based ECG evidence of AF.

Secondary outcomes

  1. Mean Change in the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) Score

    Time frame: 6 months, 1 year

    Atrial Fibrillation Effect on Quality-of-Life will be measured using the AFEQT, the score ranges from 0 to 100, with higher scores indicating better quality of life

Study contacts

Contact information is provided by the study sponsor or research team.

Bella Peña, BA

CONTACT

[email protected]

415-502-3053

Hannah Oo, BS

CONTACT

[email protected]

415-476-4999

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • American College of Cardiology

Registry information

Acronym: VIBRANT-AF

Important dates

Study start
2022
Primary completion
2026
Study completion
2027
First posted
Aug 17, 2022
Registry last updated
Jan 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.